Skip to main content

Table 2 Lumefantrine pharmacokinetic parameters following six-dose artemether-lumefantrine treatment in HIV-1 infected patients who are antiretroviral-naïve or on lopinavir-based antiretroviral therapy

From: The interaction between artemether-lumefantrine and lopinavir/ritonavir-based antiretroviral therapy in HIV-1 infected patients

Parameter median (IQR)

ARV-naïve group (n = 18)

Lopinavir group (n = 16)

p value

Cmax (μg/mL)

8.76 (7.80–9.84)

28.15 (14.00–32.95)

<0.0001

CV

26.3 %

59.6 %

Tmax (h)

42 (42–66)

67 (51–70)

0.031

CV

35.5 %

27.1 %

AUC(0-inf) (μg.h/mL)

445 (357–553)

2478 (1093–3596)

<0.0001

CV

33.5 %

71.0 %

T1/2 (days)

4.1 (2.7–4.4)

4.6 (4.4–5.2)

0.003

CV

25.7 %

15.4 %

Day-7 conc (ng/mL)

336 (230–396)

3170 (1440–5085)

<0.0001

CV

54.0 %

98.5 %

  1. Values are shown as medians (interquartile ranges [IQRs]) and Coefficient of variation (CV, %). Cmax, maximal concentration; Tmax, time at the maximal concentration; AUC(0-inf), area under the plasma concentration-time curve, from 0 h to infinity; t1/2, elimination half-life; Day-7 concentration, lumefantrine concentration on day-7;. Statistical significance (p values) calculated using the Kruskal-Wallis test
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us